API
< Back to all clusters
[BUSINESS] · Switzerland, United States · 7 sources

started · updated

Windward Bio raises $225 million in Nasdaq debut

Windward Bio, a Basel-based biotechnology company, has priced its Nasdaq initial public offering at $17 per share. The company expects to raise $175 million from public investors and an additional $50 million through a private placement with Sanofi, which includes shares and pre-funded warrants.

The total financing of $225 million is intended to fund clinical trials for next-generation biologic drugs. Windward is currently focusing on treatments for asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. A primary candidate, WIN378, is a long-acting antibody designed to block TSLP. Unlike existing monthly injections, WIN378 aims to offer dosing every six months and claims higher potency than current blockbuster treatments.

Windward utilizes a model of licensing clinical-stage assets from Chinese biotech firms, including programs from Sichuan Kelun-Biotech Biopharmaceutical, Harbour BioMed, and Qyuns Therapeutics. The company is led by CEO Luca Santarelli and has attracted approximately $590 million in total equity funding since its founding.

Entities

Basel · Luca Santarelli · Nasdaq · Sanofi · Windward Bio